Product Program year 2019 Source: CMS Open Payments

Actos

Drug Diabetes

NDC 64764-301-14

Open in the dashboard

General payments

$25,131

11 payments

Research payments

$830,511

90 payments

Through program year 2019, $25,131 in general payments and $830,511 in research payments were reported against Actos (Diabetes).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2019 General $25,131 11
2019 Research $830,511 90

Breakdown

Who paid General payments · program year 2019
  1. Takeda Pharmaceuticals International, Inc. $25,050 5 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $81 6 payments
Top recipients General payments · program year 2019
  1. Vivian Fonseca Endocrinology, Diabetes & Metabolism · New Orleans, LA $25,050 100% · 5 payments
  2. Sonya Ventour Gastroenterology · Baldwin, NY $21 <1% · 1 payment
  3. James Beitzel Family Medicine · Columbia City, IN $14 <1% · 1 payment
  4. Gary Berube Family Medicine · Columbia City, IN $14 <1% · 1 payment
  5. Joel Jose Valcarcel Family Medicine · Roanoke, IN $14 <1% · 1 payment

The top 5 of 7 recipients; each share is of general payments naming this product in 2019.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2019
  1. Endocrinology, Diabetes & Metabolism Internal Medicine $25,050 100% · 1 practitioner
  2. Family Medicine $54 <1% · 4 practitioners
  3. Gastroenterology Internal Medicine $27 <1% · 2 practitioners

Each share is of general payments naming this product to practitioners with a specialty in 2019. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2019
  1. Louisiana $25,050 100% · 1 recipient
  2. Indiana $54 <1% · 4 recipients
  3. New York $21 <1% · 1 recipient
  4. Michigan $6 <1% · 1 recipient

Each share is of general payments naming this product in 2019 where a state was reported.

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

127

Prescriptions dispensed, refills included

Drug cost

$78,209

Paid at the pharmacy, in all

Prescribers

10

With 11 or more claims of it

Medicare Part D drugs matched to Actos, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Actos Pioglitazone Hcl Same name 10 127 $78,209

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 10 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Isaac Snapp Physician Assistant SC 16 $19,112 None on record
Hy Phung Ngo Internal Medicine CA 14 $8,719 None on record
Carl Gibson Endocrinology VA 13 $7,417 None on record
Alvin Chang Internal Medicine CA 13 $7,390 None on record
David Rubin Internal Medicine MA 13 $4,871 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See all 10 in the dashboard with a free account
11 general · 90 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2019

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record